(Q34368381)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15546967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

1 reference

title

Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15546967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15546967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Thompson AE

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15546967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

16 November 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15546967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15546967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15546967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15546967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

145-150

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15546967%20AND%20SRC:MED&resulttype=core&format=json

Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Clinical and rheological effects of nifedipine in Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Nifedipine in the treatment of Raynaud's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390

Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEH390